Acura completes Nexafed transition to MainPointe with new formulation on horizon

PALATINE, Ill. — Acura Pharmaceuticals on Monday reported the completed transition of Nexafed and Nexafed Sinus to MainPointe Pharmaceuticals as that company commences selling activities with a new formulation coming to market soon.



"Consistent with our strategy to secure licensing partners to commercialize our product technologies, in March the company licensed Nexafed and Nexafed Sinus to MainPointe Pharmaceuticals and recorded license fee revenue of $2.5 million," Peter Clemens, SVP and CFO Acura, told analysts earlier this week. "We expect the sales to grow significantly over current levels as MainPointe brings their commercial expertise to bear to penetrate the pharmacy market."



MainPointe will be bringing to market Nexafed 2.0, added Bob Jones, Acura president and CEO. "We have completed manufacturing validation for Nexafed with our [microparticle] 2.0 formulation," he said. "The output from these batches has been transferred to MainPointe and is available for sale. We expect MainPointe will introduce Nexafed 2.0 to the market in this the third quarter."



"Conversion of pseudoephedrine products into methamphetamine remains an acute problem in many communities," John Schutte, MainPointe chairman and CEO, noted earlier this year in acquiring the rights to market Nexafed.  "The Nexafed products have proven to be a success in curbing this costly problem and we look forward to driving this business forward."